Distinct patterns of T-cell exhaustion and immune dysfunction have been associated with suboptimal response and early progression after both CART and TCE.38,39 To further investigate this, we analyzed immune profiles using scRNA-seq from the 11 patients described above and integrated these data with 6 previously published patients32 treated with anti-BCMA CART (Fig 3A). This evidence concerns the gene TNFRSF17 and immune system disorder.